|
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
In 236 patients with AF receiving VKAs, we measured ex vivo plasma clot lysis time (CLT), a measure of global fibrinolysis along, with von Willebrand factor antigen (vWF), plasminogen activator inhibitor 1 antigen (PAI-1), and other fibrinolysis modulators.
|
31740169 |
2020 |
|
Atrial Fibrillation
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The analysis found that high vWF levels were associated with increased risks of all-cause death (RR 1.56; 95% CI 1.16 to 2.11, p=0.00400), cardiovascular death (RR 1.91; 95% CI 1.20 to 3.03, p=0.00600), MACE (RR 1.83; 95% CI 1.28 to 2.62, p=0.00090), stroke (RR 1.69; 95% CI 1.08 to 2.64, p=0.02000) and bleeding (RR 2.01; 95% CI 1.65 to 2.45, p<0.00001) in patients with AF.
|
31771966 |
2019 |
|
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
Median concentrations of TF and vWF were approximately 40% and 30% higher, respectively, in the AF group than in the control group, while no significant differences in levels of cf-DNA, PPLs, or total submicron particles were observed.
|
30530119 |
2019 |
|
Atrial Fibrillation
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Patients with AF recurrence seem to have elevated vWF expression and decreased TM expression.
|
29547930 |
2018 |
|
Atrial Fibrillation
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Patients with AF with elevated vWF level are independently associated with a higher risk of MACEs and all-cause mortality.
|
29979393 |
2018 |
|
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
Is von Willebrand factor associated with stroke and death at mid-term in patients with non-valvular atrial fibrillation?
|
29685722 |
2018 |
|
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
Circulating plasma levels of plasminogen activator inhibitor 1 (PAI-1), CD40-ligand (CD40-L), nucleosomes (which are indicators of cell death), C-reactive protein (CRP), procollagen III N-terminal propeptide (PIIINP), procollagen III C-terminal propeptide (PIIICP), procollagen I N-terminal propeptide, tissue plasminogen activator, and von Willebrand factor were analyzed as potential biomarkers of AF.
|
29558818 |
2018 |
|
Atrial Fibrillation
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Patients with AF without oral anticoagulation (OAC) had significantly higher vWF plasma levels (154.00 [75-201] UI/dL) and vWF activity (60.00% [20%-210%]) compared to patients with OAC (133.50 [90-192] UI/dL, P = <.001; 50.00% [20%-160%], P = .02).
|
28618874 |
2018 |
|
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
von Willebrand Factor is steadily elevated throughout the course of dysrhythmia in NVAF patients treated with warfarin and in those with higher intensity of left atrium blood stasis.
|
28952167 |
2017 |
|
Atrial Fibrillation
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Levels of FVIII and VWF were significantly elevated in the FV and LA of AF patients as compared to controls.
|
28713823 |
2017 |
|
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
Von Willebrand factor and ADAMTS13 plasma in older patients with high CHA2DS2-VASc Score with and without atrial fibrillation.
|
29164570 |
2017 |
|
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
For major bleeding, the addition of vWF to HAS-BLED improved the c-index but not IDI or NRI.DCA showed minimal net benefit. vWF acts as a simple prognostic biomarker in AF and, whilst its addition to current scores statistically improves prediction for some endpoints, absolute changes and impact on clinical decision-making are marginal.
|
28134282 |
2017 |
|
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
BEFREE |
We sought to determine the diagnostic validity of plasma biomarkers of i) inflammation (marked by interleukin-6 [IL-6] and high-sensitivity C-reactive protein [hs-CRP]), ii) extracellular matrix remodelling (matrix metalloproteinase [MMP-9], tissue inhibitor of matrix metalloproteinase [TIMP-1]) and iii) the prothrombotic state (tissue factor and von Willebrand factor [vWF]) in the risk prediction of post-operative AF.
|
20458440 |
2010 |
|
Atrial Fibrillation
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Impaired flow mediated dilatation as evidence of endothelial dysfunction in chronic atrial fibrillation: relationship to plasma von Willebrand factor and soluble E-selectin levels.
|
17996280 |
2008 |
|
Atrial Fibrillation
|
0.400 |
Biomarker
|
disease |
CTD_human |
Soluble E-selectin, von Willebrand factor, soluble thrombomodulin, and total body nitrate/nitrite product as indices of endothelial damage/dysfunction in paroxysmal, persistent, and permanent atrial fibrillation.
|
17890461 |
2007 |
|
Atrial Fibrillation
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Endocardial overexpression of vWF may occur during the process of atrial structural remodeling contributing to the thrombotic predilection of AF in association with underlying heart disease.
|
15056828 |
2004 |